Cosmo Pharmaceuticals announces expansion of agreement with Dr. Falk Pharma for Rifamycin SV MMX
Cosmo Pharmaceuticals N.V. announced today that it has expanded its existing license agreement with Dr. Falk Pharma Gmbh (“Dr. Falk”) to include Rifamycin SV MMX in the new 600mg formulation currently tested in the IBS-D indication.